Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005803 · ClinicalTrials.gov registry record · Phase 1
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT00005803 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 76 participants.
The verdict
NCT00005803, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect).
Interventions
- DRUG Cyclophosphamide
- DRUG Carmustine
- DRUG Cyclosporine
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
- PROCEDURE Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 1999-09 |
| Est. Completion | 2018-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005803
The ClinicalTrials.gov registry entry for NCT00005803 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00005803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005803 about?
NCT00005803 is a clinical study titled "Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma". This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to...
What is the current status of trial NCT00005803?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 1999-09. Estimated completion is 2018-10.
What interventions are being tested in trial NCT00005803?
The interventions under investigation include: Cyclophosphamide (DRUG), Carmustine (DRUG), Cyclosporine (DRUG), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE), Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00005803?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.